Collagen Medical

Collagen Medical is a private, pre-clinical stage biotech focused on addressing a major unmet need in chronic disease management: the precise detection and quantification of fibrosis. Its core platform involves targeted MRI contrast agents designed to bind specifically to collagen, the key protein in fibrotic tissue, enabling non-invasive, organ-wide visualization of disease progression. The company's initial focus is on fibrotic conditions linked to heart failure, liver diseases, and pulmonary fibrosis, with a secondary application in imaging cardiac perfusion for coronary artery disease. As a pre-revenue entity, its near-term goals revolve around advancing its lead candidates through preclinical validation and into clinical trials.

Proprietary platform for developing targeted MRI contrast agents that bind specifically to collagen for non-invasive, 3D mapping of fibrosis and assessment of myocardial perfusion.

Competes with improved non-contrast MRI techniques (e.g., T1/T2 mapping, elastography) and other companies developing targeted molecular imaging agents. May face future competition from large contrast agent manufacturers (Bayer, Guerbet) if they pursue similar collagen-targeting strategies.